Q4 2024 Draegerwerk AG & Co KGaA Earnings Call Transcript
Key Points
- Draegerwerk AG & Co KGaA (WBO:DRW3) achieved a robust business performance in 2024 with significant improvement in profitability.
- The company's EBIT margin increased from 4.9% to 5.8%, exceeding expectations.
- Despite a decline in the Chinese market, Draegerwerk AG & Co KGaA successfully compensated with substantial growth in other regions.
- The safety division showed strong performance, with a 28% increase in EBIT and a margin of 11.3%.
- The company plans to distribute around 30% of group net profit to shareholders, resulting in a dividend increase.
- Net sales were slightly below expectations, remaining stable at around 3.4 billion, matching the prior year.
- The medical division experienced a decline in net sales by roughly 3% due to challenging market conditions in China.
- The company faces potential risks from tariffs, which could impact operating profit if implemented.
- There is uncertainty regarding the timing of the FDA's final decision on lifting the warning letter.
- The Chinese market saw a significant decline, impacting overall performance, with expectations of only slight recovery in 2025.
Good afternoon and thank you for joining our conference call on our financial results for the fiscal year 2024. I have with me today Gerard Bresco, CFO, as well as Tom Fisher and Nicholas Hammerschmidt, both investor relations. We would like to take you through the results for the presentation that we made available on our web page this morning. Following the presentation, we will open the floor to your question.
Let's get started on page 5 for the business highlights.
2024 was a successful year for Draga with a robust business performance and the significant improvement in profitability.
While net sales were slightly below our expectations, we maintained a strong performance, achieving around 3.4 billion matching the prior year figure.
This is an outstanding achievement considering that we benefited from strong catch-up effects in 23 driven by the improved delivery capabilities and a search in demand for ventilators in China.
And importantly, although
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
